Skip to main content

Advertisement

SpringerLink
Log in

Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation

  • Pharmacologic Therapy (W.H.W. Tang, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

We describe contraception for two groups of women: (1) women with heart failure and (2) women with cardiac transplantation.

Recent Findings

Medical Eligibility Criteria for contraceptive agents address women with peripartum cardiomyopathy and women with valvular heart disease (Curtis et al. MMWR Recomm Rep 65:1–103, 2016). Recommendations for women with other forms of heart failure are extrapolated from these populations. Recommendations for women with cardiac transplantation have shifted since the 1980s: use of long-acting reversible contraception has increased, and there is a better understanding of the interactions between contraceptive and immunosuppressive regimens.

Summary

Women with heart failure may utilize long-acting reversible contraception and permanent sterilization. Modifications should be made according to the specific etiology of the heart failure. In women with cardiac transplantation, pregnancy is high risk and should be avoided altogether for 1–2 years after transplantation. In uncomplicated transplantation, almost all forms of contraception are allowable. In complicated transplantation, combined hormonal contraceptives are contraindicated, and de novo IUD insertion is not recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Estensen M, Gude E, Ekmehag B, Lommi J, Bjortuft O, Mortensen S, et al. Pregnancy in heart- and heart/lung recipients can be problematic. Scand Cardiovasc J. 2011;45:349–53.

    Article  PubMed  Google Scholar 

  2. Grewal J, Silversides CK, Colman JM. Pregnancy in women with heart disease: risk assessment and management of heart failure. Heart Fail Clin. 2014;10:117–29.

    Article  PubMed  Google Scholar 

  3. Abdalla M, Mancini DM. Management of pregnancy in the post-cardiac transplant patient. Semin Perinatol. 2014;38:318–25.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009;95:680–6.

    Article  PubMed  Google Scholar 

  5. •• Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103. The Centers for Disease Control and Prevention Medical Eligibility Criteria (CDC-MEC) document provides guidelines for use of contraceptive agents in multiple different populations, including patients with cardiac risk factors, heart failure, and solid organ transplantation.

    Google Scholar 

  6. • World Health Organization Medical Eligibility Criteria for Contraceptive Use, Fifth Edition. Geneva. 2015. WHO reference number: WHO/RHR/15.07. The World Health Organization Medical Eligibility Criteria document also provides guidelines for mutiple different populations.

  7. • World Health Organization Medical Eligibility Criteria for Contraceptive Use, Fourth Edition. Geneva. 2010. The World Health Organization Medical Eligibility Criteria document also provides guidelines for mutiple different populations.

  8. • Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR, Doria C, McGrory CH, Armenti VT. Report from the national transplantation pregnancy registry (ntpr): outcomes of pregnancy after transplantation. Clin Transpl. 2010;7:65–85. The NTPR collects outcome data on patients with solid organ transplant, including cardiac transplant, who undergo pregnancy.

  9. Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart. 2006;92:1520–5.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Tran DD, Kobashigawa J. A review of the management of pregnancy after cardiac transplantation. Clin Transpl. 2015;31:151–61.

    PubMed  Google Scholar 

  11. Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care. 2008;34:237–46.

    Article  PubMed  Google Scholar 

  12. Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10:1–10.

    Article  CAS  PubMed  Google Scholar 

  13. Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gulmezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev. 2011;11(5):CD004861. https://doi.org/10.1002/14651858.CD004861.pub2.

  14. Erkkola R, Landgren BM. Role of progestins in contraception. Acta Obstet Gynecol Scand. 2005;84:207–16.

    Article  PubMed  Google Scholar 

  15. Giribela CR, Consolim-Colombo FM, Nisenbaum MG, Moraes TL, Giribela AH, Baracat EC, et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015;31:912–5.

    Article  CAS  PubMed  Google Scholar 

  16. Nisenbaum MG, de Melo NR, Giribela CR, de Morais TL, Guerra GM, de Angelis K, et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014;175:62–6.

    Article  CAS  PubMed  Google Scholar 

  17. Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet. 1997;59:237–43.

    Article  CAS  PubMed  Google Scholar 

  18. Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin N Am. 2011;40:419–32. ix

    Article  CAS  Google Scholar 

  19. Christy NP, Shaver JC. Estrogens and the kidney. Kidney Int. 1974;6:366–76.

    Article  CAS  PubMed  Google Scholar 

  20. Khalil RA. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol. 2013;86:1627–42.

    Article  CAS  PubMed  Google Scholar 

  21. Stachenfeld NS. Hormonal changes during menopause and the impact on fluid regulation. Reprod Sci. 2014;21:555–61.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8–15.

    Article  CAS  PubMed  Google Scholar 

  23. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.

    Article  CAS  PubMed  Google Scholar 

  24. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3(3):CD010813. https://doi.org/10.1002/14651858.CD010813.pub2.

  25. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183:E1319–25.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Sedlak T, Shufelt C, Iribarren C, Lyon LL, Bairey Merz CN. Oral contraceptive use and the ecg: evidence of an adverse qt effect on corrected qt interval. Ann Noninvasive Electrocardiol. 2013;18:389–98.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex hormones and the qt interval: a review. J Women's Health (Larchmt). 2012;21:933–41.

    Article  Google Scholar 

  30. Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ. Oral contraceptive use and the risk of cardiac events in patients with long qt syndrome. Heart Rhythm. 2014;11:1170–5.

    Article  PubMed  Google Scholar 

  31. Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95:130–9.

    Article  CAS  PubMed  Google Scholar 

  32. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (chcs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87:93–100.

    Article  CAS  PubMed  Google Scholar 

  33. Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception. 2004;69:89–97.

    Article  CAS  PubMed  Google Scholar 

  34. Wang Q, Wurtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45:1445–57.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev. 2013;13(11):CD007541. https://doi.org/10.1002/14651858.CD007541.pub3.

  36. Dilshad H, Ismail R, Naveed S, Usmanghani K, Alam MT, Sarwar G. Effect of hormonal contraceptives on serum lipids: a prospective study. Pak J Pharm Sci. 2016;29:1379–82.

    CAS  PubMed  Google Scholar 

  37. Kongsayreepong R, Chutivongse S, George P, Joyce S, McCone JM, Garza-Flores J, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of dmpa and a control group of iud users. World Health Organization. Task force on long-acting systemic agents for fertility regulation special programme of research, development and research training in human reproduction. Contraception. 1993;47:177–91.

    Article  CAS  PubMed  Google Scholar 

  38. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112:788–99.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Villas-Boas J, Vilodre LC, Malerba H, Pontremoli Salcedo M, Foresti Jimenez M, El Beitune P. Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period. Eur J Obstet Gynecol Reprod Biol. 2016;202:51–4.

    Article  CAS  PubMed  Google Scholar 

  40. Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in adolescents: evaluation of clinical aspects. Contraception. 2011;83:336–9.

    Article  CAS  PubMed  Google Scholar 

  41. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ. Influence of oral progesterone administration on drug-induced qt interval lengthening: a randomized, double-blind, placebo-controlled crossover study. JACC Clin Electrophysiol. 2016;2:765–74.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Zigler RE, McNicholas C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol. 2017;216:443–50.

    Article  CAS  PubMed  Google Scholar 

  43. Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212:50 e51–8.

    Article  Google Scholar 

  44. Moss C, Isley MM. Sterilization: a review and update. Obstet Gynecol Clin N Am. 2015;42:713–24.

    Article  Google Scholar 

  45. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375:555–62.

    Article  CAS  PubMed  Google Scholar 

  46. Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2017;8:CD001324.

    PubMed  Google Scholar 

  47. Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015;36:1728–34. 1734a-1734b

    Article  PubMed  Google Scholar 

  48. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15–21.

    Article  CAS  PubMed  Google Scholar 

  49. Scala C, Leone Roberti Maggiore U, Remorgida V, Venturini PL, Ferrero S. Drug safety evaluation of desogestrel. Expert Opin Drug Saf. 2013;12:433–44.

    Article  CAS  PubMed  Google Scholar 

  50. Bianca I, Geraci G, Gulizia MM, Egidy Assenza G, Barone C, Campisi M, et al. Consensus document of the Italian Association of Hospital Cardiologists (anmco), Italian Society of Pediatric Cardiology (sicp), and Italian Society of Gynaecologists and Obstetrics (sigo): pregnancy and congenital heart diseases. Eur Heart J Suppl. 2017;19:D256–92.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation. 2007;116:1736–54.

    Article  PubMed  Google Scholar 

  52. Yu AF, Steingart RM, Fuster V. Cardiomyopathy associated with cancer therapy. J Card Fail. 2014;20:841–52.

    Article  PubMed  Google Scholar 

  53. Casey PM, Faubion SS, MacLaughlin KL, Long ME, Pruthi S. Caring for the breast cancer survivor's health and well-being. World J Clin Oncol. 2014;5:693–704.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Bordignon S, Aramayo AM, Nunes e Silva D, Grundler C, Nesralla I. Pregnancy after cardiac transplantation. Report of one case and review. Arq Bras Cardiol. 2000;75:515–22.

    Article  CAS  PubMed  Google Scholar 

  55. McKay DB, Josephson MA, Armenti VT, August P, Coscia LA, Davis CL, et al. Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant. 2005;5:1592–9.

    Article  PubMed  Google Scholar 

  56. • Cimino FM, Snyder KA. Primary care of the solid organ transplant recipient. Am Fam Physician. 2016;93:203–10. Review of common medical issues affecting patients with solid organ transplant.

    PubMed  Google Scholar 

  57. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.

    Article  PubMed  Google Scholar 

  58. Krajewski CM, Geetha D, Gomez-Lobo V. Contraceptive options for women with a history of solid-organ transplantation. Transplantation. 2013;95:1183–6.

    Article  CAS  PubMed  Google Scholar 

  59. • Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116–25. Review of management of pregnancy in patients with solid organ transplantation, including discussion of appropriate contraception counseling.

    PubMed  PubMed Central  Google Scholar 

  60. Rafie S, Lai S, Garcia JE, Mody SK. Contraceptive use in female recipients of a solid-organ transplant. Prog Transplant. 2014;24:344–8.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16(Suppl 1):121–4.

    Article  CAS  PubMed  Google Scholar 

  62. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990;323:693–9.

    Article  CAS  PubMed  Google Scholar 

  63. Bennett AL, Ventura HO. Hypertension in patients with cardiac transplantation. Med Clin North Am. 2017;101:53–64.

    Article  PubMed  Google Scholar 

  64. Agarwal A, Prasad GV. Post-transplant dyslipidemia: mechanisms, diagnosis and management. World J Transplant. 2016;6:125–34.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008;3 Suppl 2:S38–48.

    Article  PubMed  Google Scholar 

  66. Huguelet PS, Sheehan C, Spitzer RF, Scott S. Use of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients: a case series. Contraception. 2017;95:378–81.

    Article  CAS  PubMed  Google Scholar 

  67. Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception. 2012;86:288–9.

    Article  CAS  PubMed  Google Scholar 

  68. Kossoy LR, Herbert CM 3rd, Wentz AC. Management of heart transplant recipients: guidelines for the obstetrician-gynecologist. Am J Obstet Gynecol. 1988;159:490–9.

    Article  CAS  PubMed  Google Scholar 

  69. Zerner J, Doil KL, Drewry J, Leeber DA. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26:99–102.

    CAS  PubMed  Google Scholar 

  70. Yadav BK, Gupta RK, Gyawali P, Shrestha R, Poudel B, Sigdel M, et al. Effects of long-term use of depo-medroxyprogesterone acetate on lipid metabolism in Nepalese women. Korean J Lab Med. 2011;31:95–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic-Fairview Hospital, 18099 Lorain Ave, Ste 245, Cleveland, OH, 44111, USA

    Anjli Maroo & Johnny Chahine

Authors
  1. Anjli Maroo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johnny Chahine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anjli Maroo.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pharmacologic Therapy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maroo, A., Chahine, J. Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation. Curr Heart Fail Rep 15, 161–170 (2018). https://doi.org/10.1007/s11897-018-0392-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-018-0392-x

Keywords

Search

Navigation